@article{b06f0af3895040ff9774b014701c2754,
title = "Quantitative risk-benefit analysis of natalizumab",
author = "Holloway, {R. G.} and Thompson, {J. P.} and K. Noyes and Dorsey, {R. R.} and Schwid, {S. R.}",
note = "Funding Information: Disclosure: K.N., R.G.H., and S.R.S. were supported in part by contract HC0071 from the National Multiple Sclerosis Society. K.N. was supported in part by research grant K01 AG 20980 from the National Institute on Aging. E.R.D. was supported in part by an American Academy of Neurology Clinical Research Training Fellowship. R.G.H. was supported in part by grant K24 NS4 2098 from the National Institute of Neurological Disorders and Stroke. S.R.S. has received research funding from Biogen, Serono, and Teva and honoraria for educational and consulting activities from Berlex, Biogen, Serono, and Teva. The project described was partially supported by grant number 1 UL1 RR024160–01 from the National Center for Research Resources (NCRR), a component of the NIH and the NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at http://www.ncrr.nih.gov/ . Information on Re-engineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp .",
year = "2009",
month = may,
day = "19",
doi = "10.1212/01.wnl.0000347020.85704.36",
language = "English (US)",
volume = "72",
pages = "1791--1792",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "20",
}